Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Nabiximols + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Nabiximols | GW-1000|Sativex|CBD/THC|GW-1000-02 | Nabiximols is a formulation containing tetrahydrocannabinol (THC) and cannabidiol (CBD), along with other cannabinoid and non-cannabinoid components, which potentially increases tumor cell death and enhances antitumor activity (PMID: 25674907, PMID: 33623076). | ||
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05629702 | Phase II | Nabiximols + Temozolomide Temozolomide | ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids (ARISTOCRAT) | Recruiting | GBR | 0 |